Children with acute leukemia are at a high risk of invasive fungal disease, which might manifest itself as clinically-resistant entity. The objective of this paper is to present an unusual clinical case of 17-year-old patient treated for acute lymphoblastic leukemia, with early development of disseminated invasive aspergillosis, involving the abdominal, pulmonary and cardiac structures. The patient was subjected to a combined targeted double, and later triple, antifungal therapy together with several debulking surgical interventions. The clinical course indicated a highly clinically-resistant invasive fungal disease, and the treatment was unsuccessful in this case. Limited current experience in triple antifungal therapy, abdominal aspergillosis, Aspergillus endocarditis, and possible causes of failure of antifungal therapy are discussed in the paper.
INTRODUCTION
Invasive fungal disease (IFD) is a systemic fungal infection which develops in patients with immune deficiencies. IFD is an opportunistic infection. Patients at a high risk of developing IFD include primarily those with hematologic malignancies, and acute leukemia in particular, and patients who had undergone allogeneic transplantation of hematopoietic stem cells and organs.
There are 3 levels of IFD diagnosis: proven, probable and possible [1] . Proven diagnosis is based on a positive result of culture harvested from a physiologically sterile location, and on an accurate identification of the pathogen, confirmed in a histopathology report. The most common type of malignancy diagnosed in pediatric patients under the age of 18 is acute lymphoblastic leukemia (ALL).
The 2012-2013 national analysis in Poland confirmed that the incidence of IFD in a group of 430 children with ALL was 13%, including 0.7% of children with proven diagnosis, 4.1% of those with probable diagnosis, and 9.5% of patients with possible diagnosis [2] .
The aim of this paper is to describe an atypical IFD case in a 17-year-old boy with ALL and with disseminated invasive aspergillosis, with massive involvement of abdominal structures (in the form of multiple abscesses) as well as of the lungs and endocardium. Due to the clinical resistance in the patient, a double antifungal therapy was administered, followed by a triple regimen, with several concurrent surgical debulking procedures.
As the course of treatment was unfavorable, the paper discusses potential causes behind the failure of antifungal therapy in immunosuppressed patients.
CASE DESCRIPTION
The paper presents the case of a 17-year-old boy with acute echinocandins with azoles and amphotericin [6] . Animal models also demonstrate a faster regression of infection, following the administration of echinocandins with amphotericin or azoles [7] .
EBMT and ECIL1 studies reported that combined therapy was identified 21 patient with acute leukemia or after hematopoietic stem cell transplants, in whom digestive tract aspergillosis developed. In most of them (13 vs. 8) , there was systemic aspergillosis. In 6 patients the diagnosis was made post mortem, and 7 out of the remaining 15 patients also died in the process. The analyzed patients received both antifungal agents as well as surgical treatment, but based on that analysis, the authors were unable to draw conclusions on an optimum management of abdominal aspergillosis [12] . Other known case reports fail to deliver unequivocal arguments in favor of particular therapeutic regimens in the treatment of invasive abdominal aspergillosis diagnosed in patients with acute leukemia or after hematopoietic stem cell transplants [13] [14] [15] .
Similarly, there is limited experience with reference to the treatment of fungal endocarditis caused by Aspergillus species in hematologic patients [16] [17] [18] [19] [20] . Many factors might have impacted the failure of antifungal treatment of massive and disseminated aspergillosis in a pediatric patient with acute lymphoblastic leukemia. They have been presented in table 1. 
SUmmARy
Triple antifungal therapy and surgical debulking procedures, aimed at reducing the fungal mass volume in the abdominal cavity and lungs was unsuccessful in the case presented above. The fundamental cause behind the failure of antifungal therapy in OncoReview 2018/Vol. 8/Nr 2/A33-37 the above described patient with acute lymphoblastic leukemia was the massive fungal infiltration of his kidneys, lungs, peripancreatic space and endocardium. Despite the multiple surgical interventions, the volume of fungal infiltrates and abscesses could not be reduced to an extent that would render pharmacotherapy effective.
